After a median follow-up of 2.4 years, patients on capecitabine were more than twice as likely to have a relapse and twice as likely to die as those receiving standard chemotherapy.

• 经过平均2.；4年的随访，与常规化疗组相比，卡培他滨治疗组有超过两倍的复发率和两倍的死亡率。